Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

Like many pharma stocks, Eli Lilly (NYSE: LLY ... commercialized as Ozempic and Wegovy. These drugs all have produced impressive results in clinical trials and in the real world, and that has ...

Eli Lilly (LLY) believes its experimental weight ... including Zepbound, Wegovy, and Ozempic. Novo Nordisk is also working on a GLP-1 weight-loss pill. Last, year the company said that patients ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

This is despite a current shortage of Ozempic (which is supposed to be prescribed only for people with type 2 diabetes), competition from US rival Eli Lilly and the cost, which means only ...